Zhang Xiaoyan Michelle 4
4 · Ikena Oncology, Inc. · Filed Jan 12, 2022
Insider Transaction Report
Form 4
Zhang Xiaoyan Michelle
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-01-10$12.00/sh−36$432→ 44,475 total - Exercise/Conversion
Common Stock
2022-01-11$2.15/sh+964$2,069→ 45,439 total - Exercise/Conversion
Common Stock
2022-01-10$2.15/sh+36$77→ 44,511 total - Sale
Common Stock
2022-01-11$12.00/sh−964$11,568→ 44,475 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-10−36→ 25,437 totalExercise: $2.15Exp: 2028-12-17→ Common Stock (36 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-11−964→ 24,473 totalExercise: $2.15Exp: 2028-12-17→ Common Stock (964 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.
- [F2]25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.